Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Impact of standard of care for psychosis in Parkinson disease.

Thomsen TR, Panisset M, Suchowersky O, Goodridge A, Mendis T, Lang AE.

J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1413-5. doi: 10.1136/jnnp.2008.153163. No abstract available.

PMID:
19010958
2.

Psychosis in Parkinson's disease: how should we treat it?

Shotbolt P, Samuel M, Anthony D.

Expert Rev Neurother. 2006 Sep;6(9):1243-6. No abstract available.

PMID:
17009911
3.

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology.

Neurology. 2006 Apr 11;66(7):996-1002.

PMID:
16606910
4.

Management of Parkinson disease.

Mandanas L.

J Am Board Fam Pract. 1998 Mar-Apr;11(2):171. No abstract available.

PMID:
9542714
6.
7.

Management of psychotic symptoms associated with the disease and its treatments.

Monias A, Samuels SC.

Geriatrics. 2001 Nov;56(11):56-7. No abstract available.

PMID:
11710816
9.

Management of non-motor complications in Parkinson's disease.

Fujimoto K.

J Neurol. 2009 Aug;256 Suppl 3:299-305. doi: 10.1007/s00415-009-5245-9. Review.

PMID:
19711120
10.

Depression, parkinsonism, and psychosis: a case report.

McDanal CE Jr, Bolman WM.

Hawaii Med J. 1981 Dec;40(12):352-3. No abstract available.

PMID:
7319799
11.

Catatonic stupor during the course of Parkinson's disease resolved with electroconvulsive therapy.

Suzuki K, Awata S, Nakagawa K, Takano T, Matsuoka H.

Mov Disord. 2006 Jan;21(1):123-4. No abstract available.

PMID:
16250024
12.

Dopamine-modulating drugs, amenorrhea-galactorrhea and neuropsychiatric illnesses.

Frye PE.

W V Med J. 1983 Aug;79(8):161-4. No abstract available.

PMID:
6138902
13.

Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning.

Rosenkilde CE.

Neurology. 2007 Apr 17;68(16):1325; author reply 1325-6. No abstract available.

PMID:
17438231
14.

Progressive external ophthalmoplegia with Parkinsonism and Dementia. Treatment with L-dopa. Report of an autopsied case.

Rajput AH, Chornell G, Rozdilsky B.

Can J Ophthalmol. 1972 Jul;7(3):368-74. No abstract available.

PMID:
5056570
15.

Clozapine treatment of parkinsonism with psychosis.

Lew MF, Waters CH.

J Am Geriatr Soc. 1993 Jun;41(6):669-71. No abstract available.

PMID:
8505467
16.

Pharmacological basis of therapeutics: dopamine receptors.

Heikkila RE.

J Med Soc N J. 1984 Dec;81(12):1084-6. No abstract available.

PMID:
6150999
17.

[Use of anticholinergic antiparkinson agents against adverse drug reactions in a psychiatric department. A quality assurance project].

Mikkelsen VR.

Ugeskr Laeger. 1998 Jul 13;160(29):4323-5. Danish. No abstract available.

PMID:
9679438
18.

Psychosis, Parkinsonism and retinitis pigmentosa.

Myers D.

Guys Hosp Rep. 1965;114(3):287-9. No abstract available.

PMID:
5294493
19.

Parkinson disease: Improving quality of care in Parkinson disease.

Schmidt P, Okun MS.

Nat Rev Neurol. 2011 Apr;7(4):196-7. doi: 10.1038/nrneurol.2011.38. Epub 2011 Mar 15. No abstract available.

PMID:
21403671
20.

Withdrawal of antiparkinson drugs.

Orlov P, Kasparian G, DiMascio A, Cole JO.

Arch Gen Psychiatry. 1971 Nov;25(5):410-2. No abstract available.

PMID:
5133814
Items per page

Supplemental Content

Write to the Help Desk